New combo aims to stop bleeding in bone marrow disease
NCT ID NCT07653581
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding a platelet-boosting drug (rhTPO) to standard cyclosporine therapy can safely raise platelet counts in 78 adults with lower-risk myelodysplastic syndromes (MDS) who have very low platelets. The goal is to reduce bleeding and the need for platelet transfusions. Participants will be randomly assigned to receive either the combination or cyclosporine alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant human thrombopoietin (rhTPO) and cyclosporine (CsA)
- What this could lead to
- If it works, this could offer a new way to raise platelet counts and reduce bleeding in people with lower-risk MDS.
- What could go wrong
- This is a small, single-center trial that hasn't started yet. The combination may not work better than cyclosporine alone, and both drugs have side effects like infection risk or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOWER-RISK MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.